Computational Bio & Chem

Showing 1–29 of 29

Company Profile

Built to break barriers: How Grove Biopharma is architecting its way around traditional drug limits

By Dr. Emily Park, Dr. Kiersten Stead

Latus Bio finds a better way to deliver genes to cells deep in the brain to help patients with neurodegeneration

By Dr. Kiersten Stead

Creyon Bio deal with Lilly brings up to $1 billion in payments for research on RNA-targeting drugs

By Dr. Kiersten Stead

Manufacturing cancer-killing T cells inside the body

By Dr. John Hamer, Dr. Kiersten Stead

DCVC Announcements

DCVC closes $700 million+ in new funds for a healthier planet and healthier lives; releases second-annual Deep Tech Opportunities Report and first-annual DCVC Climate Impact Report

DCVC Bio III closes at $400 million

By Dr. John Hamer, Dr. Kiersten Stead, Matthew Ocko, Zachary Bogue

Umoja gets FDA approval to begin clinical trials of its transformative in vivo gene therapy for cancer

By Dr. Kiersten Stead, Dr. John Hamer

DCVC co-leads $12.5 million financing for Kanvas Biosciences to boost immunotherapy by mapping beneficial gut bacteria

By Jason Pontin

How Noetik uses images to give its AI model a deeper understanding of cancer

Ascend partners with industry to drive down gene therapy cost for better patient access

Radionetics announces $52.5 million Series A round co-led by DCVC Bio

Deep Tech Opportunities Report

Cryptography for the real world

Deep Tech Opportunities Report

The Engineered Patient

MycoWorks expands to address the soaring need for high-end leather alternatives

By Dr. Kiersten Stead

With Assets from Federation Bio, Kanvas Aims to Replace Imprecise Microbiome Therapies with a Single, Rationally Designed Pill

By Jason Pontin

DCVC Leads $14 Million Seed Round for Noetik

By James Hardiman

Deep Tech Opportunities Report

Predictive drug development: toward efficacy from the get-go

DCVC leads $12M financing for Kanvas Biosciences to map the human body’s undiscovered territory: the microbiome

By Jason Pontin

DCVC leads $13 million seed funding for ShennonBio—revolutionizing immunotherapy through immune cell profiling at unprecedented accuracy, speed

By James Hardiman

DCVC Announcements

DCVC Welcomes 2022

Biology-as-a-Platform in the Fight Against Cancer: Freenome Raises $270m Series C

By Zachary Bogue

DCVC Announcements

2021 and Deep Tech: Reasons for Optimism

Using Biology-as-a-Platform to Move from Treatment to Cure

By Zachary Bogue

Life sciences and Deep Tech: The next set of solutions to the next set of problems

By Dr. Kiersten Stead, Dr. John Hamer, Matthew Ocko, Zachary Bogue

An Update on How Deep Tech is Arming the Fight Against COVID-19

By Matthew Ocko, Zachary Bogue

Powering a Comprehensive Response to the COVID-19 Crisis Through Deep Tech

By Matthew Ocko, Zachary Bogue

Reimagining biologics: AbCellera and Novartis partner to find new disease treatments

By Dr. John Hamer

AbCellera Raises $10M Series A: Deep Search for the Immune System

By Matthew Ocko, Zachary Bogue

DCVC Bio leads GenEdit’s $8.5 Million Seed Round: Safe, efficient CRISPR and gene therapy delivery platform proven across multiple diseases and cell types

By Matthew Ocko, Zachary Bogue

Explore Content Topics

View All

Computational Bio & Chem 29

Cybersecurity, Security, & Defense 17

Enterprise Enablement 7

Finance & Insurance 3

Foundational Technology 9

Industrial Transformation 31

Smart Agriculture 16